Iron restriction in sickle cell disease: When less is more

Area of Science:

• Hematology
• Genetic Blood Disorders
• Anemia Research

Background:

• Sickle cell disease (SCD) is characterized by the polymerization of hemoglobin S (HbS).
• Clinical manifestations of SCD are linked to intracellular HbS concentration.
• Anemia is a hallmark of SCD.

Purpose of the Study:

• To explore the potential therapeutic benefit of iron restriction in sickle cell disease.
• To evaluate if iron deficiency could ameliorate SCD symptoms.

Main Methods:

• Review of published literature including basic science, animal models, and noncontrolled clinical observations.
• Analysis of the relationship between iron deficiency, hemoglobin concentration, and HbS polymerization.

Main Results:

• Evidence suggests iron restriction may reduce HbS polymerization.
• Iron deficiency lowers erythrocyte hemoglobin concentration, potentially mitigating SCD pathology.
• Therapeutic potential of iron restriction in SCD is supported by existing data.

Conclusions:

• Iron restriction may offer a beneficial strategy for managing sickle cell disease.
• Further well-designed clinical studies are needed to confirm the safety and efficacy of iron restriction in SCD.
• Emerging pharmacologic agents may offer alternative methods to reduce red cell hemoglobin concentrations.